← Back to Search

Antiviral Agent

Group A for Chronic Obstructive Pulmonary Disease

Phase 1
Waitlist Available
Led By David Wyatt, MD
Research Sponsored by Altesa Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to 3 weeks
Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of vapendavir, an antiviral agent, in healthy and COPD patients. Up to 24 adults will be included; follow-up will last 14-30 days.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease
  • Respiratory Diseases
  • Lower Respiratory Infection
  • Lung Disease
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to 3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetic Analyses

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group BExperimental Treatment1 Intervention
Participants with COPD
Group II: Group AExperimental Treatment1 Intervention
Healthy Participants (HP)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vapendavir
2015
Completed Phase 2
~460

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Altesa Biosciences, Inc.Lead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
David Wyatt, MDPrincipal InvestigatorVP Medical Affairs
3 Previous Clinical Trials
166 Total Patients Enrolled
~12 spots leftby May 2025